Holen Sie sich die Stockscreener-App
8.76
3.67%
0.31
Handel nachbörslich:
8.76
Schlusskurs vom Vortag:
$8.45
Offen:
$8.5
24-Stunden-Volumen:
1.58M
Relative Volume:
1.19
Marktkapitalisierung:
$1.39B
Einnahmen:
$53.61M
Nettoeinkommen (Verlust:
$-142.52M
KGV:
-7.8919
EPS:
-1.11
Netto-Cashflow:
$-141.83M
1W Leistung:
+2.46%
1M Leistung:
+13.77%
6M Leistung:
-18.89%
1J Leistung:
+57.27%
1-Tages-Spanne:
$8.42
$9.03
1-Wochen-Bereich:
$7.80
$9.03
52-Wochen-Spanne:
$5.04
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Vergleichen Sie WVE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
8.76 | 1.29B | 53.61M | -142.52M | -141.83M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
Wave Life Sciences Shareholders Approve Key Proposals - MSN
Will Weaker Sales and Deeper Losses Shift Wave Life Sciences' (WVE) Investment Narrative? - simplywall.st
Is Wave Life Sciences Ltd. the Top Chart Pick This WeekAI Based High Gain Watchlist Scanner Shared - beatles.ru
Wave Life Sciences is a new Buy at Canaccord Genuity on near-term catalysts - MSN
Wave Life Sciences Director Sells 1,127 Shares for $8.75 Each. - AInvest
Oppenheimer Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $24 - 富途牛牛
CCORF Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $19 - 富途牛牛
Wave Life Sciences Highlights RNA Platform Advancements - TipRanks
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $18 to $24 - 富途牛牛
Wave Life Sciences stock a new Buy at Canaccord Genuity (WVE) - Seeking Alpha
Wave Life Sciences stock initiated with Buy rating by Canaccord - Investing.com Australia
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wave Life Sciences Ltd. shares rise 6.03% premarket after OraSure Technologies appoints new Chief Commercial Officer. - AInvest
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13% - simplywall.st
Wave Life Sciences signals key Q3 and Q4 data catalysts as INHBE and AATD programs advance - MSN
When is Wave Life Sciences Ltd. stock expected to show significant growthSuperior stock growth - Jammu Links News
What analysts say about Wave Life Sciences Ltd. stockConsistent triple-digit returns - Jammu Links News
Earnings Update: Wave Life Sciences Ltd. (NASDAQ:WVE) Just Reported And Analysts Are Trimming Their Forecasts - 富途牛牛
How many analysts rate Wave Life Sciences Ltd. as a “Buy”Triple-digit wealth increases - Jammu Links News
What are analysts’ price targets for Wave Life Sciences Ltd. in the next 12 monthsUnlock powerful trading strategies for gains - Jammu Links News
What is Wave Life Sciences Ltd. company’s growth strategyDiscover undervalued stocks ready to soar - Jammu Links News
Is Wave Life Sciences Ltd. a growth stock or a value stockExceptional profit potential - Jammu Links News
What are the latest earnings results for Wave Life Sciences Ltd.Capitalize on emerging market sectors - Jammu Links News
How does Wave Life Sciences Ltd. compare to its industry peersBuild a portfolio that withstands market volatility - Jammu Links News
Insights Into WAVE Life Sciences's Upcoming Earnings - 富途牛牛
How strong is Wave Life Sciences Ltd. company’s balance sheetSmart Portfolio Outlook For Consistent Profits - Jammu Links News
Why is Wave Life Sciences Ltd. stock attracting strong analyst attentionPost Market Updates For Consistent Profits - Jammu Links News
Wave Life Sciences Ltd. shares rise 2.72% intraday after TELUS CORPORATION's ESG initiatives and new product focus. - AInvest
WAVE Life Sciences Reports Q2 2025 Earnings: RNA Editing Progress Amid Revenue Decline and Strong Cash Position - AInvest
Wave Life Sciences Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2025 Earnings Call Transcript - Insider Monkey
Need To Know: The Consensus Just Cut Its Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates For 2025 - Yahoo Finance
Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Is it the right time to buy Wave Life Sciences Ltd. stockStock Strategy Recommendation From AI Tools - jammulinksnews.com
Wave (WVE) Q2 Revenue Drops 56% - AOL.com
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up - simplywall.st
What catalysts could drive Wave Life Sciences Ltd. stock higher in 2025Expert Picks Tips For Beginners - Jammu Links News
Wave Life Sciences: Q2 Earnings Snapshot - Huron Daily Tribune
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
WAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Call Highlights: Progress in RNA Editing Amid ... - Yahoo Finance
Wave (WVE) Q2 Revenue Drops 56% - The Motley Fool
Wave Life Sciences Advances RNA Medicine Pipeline - TipRanks
WAVE Life Sciences Q2 2025 Earnings Call Transcript - MarketBeat
Wave Life Sciences 2025 Q2 Earnings Revenue Drops 56%, Net Loss Widens - AInvest
Top Risks to Consider Before Buying Wave Life Sciences Ltd. StockOversold Recovery Opportunity Stocks Attract Buyers - metal.it
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
WaveLife Flat on Q2 Results - Baystreet.ca
WAVE Life Sciences Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Wave Life Sciences Ltd-Aktie (WVE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tan Aik Na | Director |
Aug 05 '25 |
Sale |
8.75 |
1,127 |
9,861 |
14,988 |
| Verdine Gregory L. | Director |
Jun 13 '25 |
Sale |
6.95 |
30,000 |
208,500 |
282,517 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):